Centessa Pharmaceuticals plc
CNTADelisted Jun 24, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001847903
Centessa Pharmaceuticals plc was delisted on Jun 24, 2026; its insiders filed their last Form 4 on Jun 24, 2026; 161 institutions reported holding it in 13F filings for Q1 2026, worth $5.90B in total; Maverick Capital was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 161
- Q1 2026, +15 vs. previous quarter
- 13F value
- $5.90B
- Reported value at the end of Q1 2026
- Superinvestors holding
- 1
- At the end of Q1 2026
Superinvestors holding CNTA, Q1 2026
1 superinvestor reports holding Centessa Pharmaceuticals plc on Form 13F. Percentages are the stock's share of each portfolio.
Maverick Capital
Lee Ainslie
0.9%
Centessa Pharmaceuticals plc's share of the portfolio
- Shares
- 1,854,488
- Value
- $73.7M
Latest insider trades
Open-market purchases and sales by Centessa Pharmaceuticals plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing)4:26 PM ET | Jun 24 | Same day | Medicxi Growth I LP and 9 others10% Owner | SSale | −20.0M | – | – | −100.0%0 after | 6 lots |
| Jun 24, 2026 (view filing)4:23 PM ET | Jun 24 | Same day | Index Ventures Life VI (Jersey) L.P. and 2 others10% Owner | SSale | −9.96M | – | – | −100.0%0 after | 2 lots |
| Mar 27, 2026 (view filing) | Mar 26 | 1 day | Anderson Karen M.Chief People Officer | SSale | −41.1K | $30.12 | −$1.24M | −39.8%62.1K after | 10b5-1 |
| Mar 26, 2026 (view filing) | Mar 26 | Same day | Weinhoff Gregory MChief Business Officer | SSale | −24.0K | $30.00 | −$719.9K | −26.7%65.9K after | 10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16-17 | 2 days | Anderson Karen M.Chief People Officer | SSale | −74.8K | $28.20 | −$2.11M | −54.6%62.1K after | 2 lots10b5-1 |
| Mar 16, 2026 (view filing) | Mar 13 | 3 days | Anderson Karen M.Chief People Officer | SSale | −120.0K | $26.25 | −$3.15M | −65.9%62.1K after | Amended2 lots10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Weinhoff Gregory MChief Business Officer | SSale | −73.2K | $26.33 | −$1.93M | −52.6%65.9K after | 2 lots10b5-1 |
| Feb 3, 2026 (view filing) | Jan 30-Feb 2 | 4 days | Hussain Iqbal JChief Legal Officer | SSale | −40.0K | $25.15 | −$1.00M | −40.9%57.6K after | 2 lots |
| Dec 9, 2025 (view filing) | Dec 9 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −10.0K | $28.83 | −$288.3K | −5.3%178.8K after | 2 lots10b5-1 |
| Dec 8, 2025 (view filing) | Dec 8 | Same day | Accardi Mario AlbertoPresident, Orexin Program | SSale | −10.0K | $30.00 | −$300.0K | −5.0%188.8K after | 10b5-1 |
Top 10 13F holders, Q1 2026
The largest institutional positions in Centessa Pharmaceuticals plc at the end of Q1 2026; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 19,963,157 | $792.9M | 80.76% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 11,430,455 | $454.0M | 4.47% | −3,125,100−21.5% | Reduced |
| Index Venture Life Associates VI Ltd | 9,961,789 | $395.7M | 100.00% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 8,925,010 | $354.5M | 0.55% | −2,356,731−20.9% | Reduced |
| Pentwater Capital Management LP | 8,170,000 | $324.5M | 2.31% | +8,170,000 | New |
| FMR LLC | 6,852,047 | $272.2M | 0.01% | −2,109,892−23.5% | Reduced |
| EcoR1 Capital, LLC | 6,000,000 | $238.3M | 10.19% | +2,885,000+92.6% | Added |
| Perceptive Advisors LLC | 5,258,903 | $208.9M | 4.13% | +2,341,269+80.2% | Added |
| Capital World Investors | 4,832,548 | $191.9M | 0.03% | +3,673,849+317.1% | Added |
| Farallon Capital Management, L.L.C. | 4,809,000 | $191.0M | 1.13% | −568,068−10.6% | Reduced |